More on AGIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $28.72 |
|
|||
| Open | $28.80 | ||||
| 52 Wk High | $71.49 | ||||
| 52 Wk Low | $33.50 | ||||
| Day High | $30.23 | ||||
| Day Low | $28.51 | ||||
| P/E | N/A | ||||
| EPS | $-1.18 | ||||
| Volume | 1,141,118 | ||||
- Agios Pharma (AGIO) PT Lowered to $31 at JPMorgan
- Agios licenses blood disorder drug from Oscotec for $25 million upfront
- Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
- Agios Pharma (AGIO) PT Lowered to $59 at Leerink
- Agios halts tebapivat development for blood cancer indication
- Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
- PYRUKYND gets EU approval for thalassaemia treatment
- Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
- Agios receives European approval for PYRUKYND to treat thalassemia
- Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
Entities mentioned with AGIO
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
